Impact Factor 5.122 | CiteScore 4.04
More on impact ›
Repair of critical-size or difficult to heal tissue defects caused by disease, malformation, trauma, or tumor resection remains a major task to achieve successfully. Starting at the end of last century, major progress has been made with regard to the transplant of “ex vivo” expanded autologous (from the patient) stem/progenitor cells, in most cases seeded on or associated to carrier biomaterials. The rapidly increasing knowledge about the physiological response of the body to injury and the signaling pathways activated during the healing process suggest that the human organism itself could provide the crucial elements needed for tissue repair and regeneration. Therefore, it appears that, parallel to the “classical” tissue engineering approach to be considered mainly in extreme and critical situations, new therapeutic strategies, aimed at the stimulation of the intrinsic endogenous potential of tissues to heal or regenerate, should be developed to make possible that a large number of patients could benefit from them.
The specialty section of Tissue Engineering and Regenerative Medicine pursues a multidisciplinary approach to the development and application of new therapeutic strategies and products for the treatment of different tissue defects and lesions. Articles submitted to the section should focus on a variety of topics such as design and production of biomimetic and intelligent scaffolds from natural and synthetic molecules, interactions between cells and biomaterials, growth factors, drug delivery, and stem cell biology. Contributions are also expected on the characterization of the interactions between cells and molecules that compose the in vivo regenerative microenvironment and the mechanisms of activation and mobilization of locally-resident and/or circulating stem/progenitor cells after the tissue injury and during the healing process. Submission of contributions dealing with pre-clinical animal trials and clinical applications, including tissue engineering and regenerative medicine approaches in all clinical disciplines are highly encouraged.
Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Semantic Scholar, Ulrich's Periodicals Directory, Science Citation Index Expanded, CLOCKSS, EI Compendex, OpenAIRE, Zetoc
PMCID: coming soon for all published articles
Tissue Engineering and Regenerative Medicine welcomes submissions of the following article types: Brief Research Report, Case Report, Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Tissue Engineering and Regenerative Medicine, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Tissue Engineering and Regenerative Medicine will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Bioengineering and Biotechnology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com